SCIENTIFIC LITERATURE · PPR

CSF Sphingolipids in Parkinson Disease and Dementia with Lewy Bodies with and without GBA1 variants

Brockmann K, Lerche S, Wurster I, Valente EM, Avenali M, Samaniego D, Martinez-Vicente M, Hernandez-Vara J, Laguna A, Sturchio A, Svenningsson P, France N, Barlow C, Sankaranarayanan S.

· 2024-07-18

DOI: 10.21203/rs.3.rs-4593604/v1

Check source for accessPreprintOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Abstract Variants in GBA1 result in dysregulated sphingolipids. We investigated five CSF sphingolipid species in a multicenter cohort comprising people with Parkinson’s Disease and Dementia with Lewy bodies with and without GBA1 variants and healthy controls. We found no increase of sphingolipid species in heterozygous GBA1 variant carriers. Sphingolipid levels had no effect on development of cognitive impairment. Thereby, CSF Sphingolipids seem not useful as state marker in Parkinson’s Disease.

Scientific assessment

Research question

Assess the question within the original study’s scope.

Methods & sample

Check the source article for study design and sample details.

Key findings

An editorially approved findings summary is not yet published for this record.

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.